Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report

The race for a COVID-19 therapeutic has attracted many of the biggest names in biopharma, and now Alexion is getting ready to place a bet on its own Soliris, GlobalData reports.

The company, which markets several rare disease medicines, plans to start a phase 2 study of Soliris in COVID-19 in the "next few days," the group reports. The study would follow a 10-patient proof-of-concept trial in which “patients improved in general," a source told GlobalData pharmaceuticals writer Reynald Castañeda.